Iovance Biotherapeutics (NASDAQ: IOVA) reported Q3 EPS of ($0.28), $0.02 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $58.6 million versus the consensus estimate of $53.88 million.

For earnings history and earnings-related data on Iovance Biotherapeutics (IOVA) click here.